Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.
| Current Price | ₹428.90 |
|---|---|
| Market Cap | ₹16,408 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Health Care; Pharmaceuticals, Biotechnology and Life Sciences; Pharmaceuticals; Pharmaceuticals; Medicinal Chemicals and Botanical Products; Pharmaceutical Contract Manufacturing Services; Pharmaceutical Contract Research Organization; Pharmaceutical Products |
| P/E Ratio | 91.6 |
| Return on Equity | 3.84% |
| 52-Week Range | ₹266.70 – ₹1,097.00 |
| Beta (1Y) | 0.91 |
| Dividend Yield | 0.00% |
1. Contract Development and Manufacturing Operations (CDMO)-100%
Cohance Lifesciences Ltd is trading at ₹428.90, with a market capitalisation of ₹16,408 Cr.
Cohance Lifesciences Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Health Care; Pharmaceuticals, Biotechnology and Life Sciences; Pharmaceuticals; Pharmaceuticals; Medicinal Chemicals and Botanical Products; Pharmaceutical Contract Manufacturing Services; Pharmaceutical Contract Research Organization; Pharmaceutical Products).
Cohance Lifesciences Ltd has a P/E of 91.6 and a return on equity of 3.84%.